SLEDAI-2K — SLE Disease Activity Index

About

The Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) was originally developed in 1985 at a consensus conference at the Hospital for Special Surgery in New York. It underwent revisions to become SLEDAI-2K, published in 2002 by Gladman et al., which allows persistent active disease descriptors to be scored rather than only new or recurrent ones. SLEDAI-2K consists of 24 weighted clinical and laboratory descriptors grouped into 9 organ systems: central nervous system (seizure, psychosis, organic brain syndrome, visual disturbance, cranial nerve disorder, lupus headache, cerebrovascular accident, vasculitis), renal (urinary casts, hematuria, proteinuria, pyuria), musculoskeletal (arthritis, myositis), mucocutaneous (rash, alopecia, mucosal ulcers), serosal (pleurisy, pericarditis), immunologic (low complement, increased DNA binding), and constitutional (fever, thrombocytopenia, leukopenia). Each descriptor is assigned a weight based on its clinical significance — CNS manifestations carry the highest weight (8 points each), followed by renal and musculoskeletal (4 points), mucocutaneous and serosal (2 points), and constitutional (1 point). The total score ranges from 0 to 105, with higher scores indicating more severe disease activity. SLEDAI-2K is the most widely used disease activity measure in SLE clinical trials and observational studies. It has been validated against physician global assessment, other disease activity indices (BILAG, ECLAM, SLAM), and demonstrates good inter-rater reliability, test-retest reliability, and responsiveness to change. The SLEDAI-2K is recommended by EULAR, ACR, and the Lupus Foundation of America for routine clinical assessment of SLE patients. Recent studies have established minimal clinically important differences (MCID) — a 4-point change is considered clinically meaningful. The SLEDAI-2K has been translated and validated in multiple languages and is used worldwide as the standard primary endpoint in SLE clinical trials, including the landmark BLISS trials for belimumab.

Formula

SLEDAI-2K Total = Sum of weights for all 24 descriptors (present/absent over past 30 days)

The SLEDAI-2K score is calculated by summing the weights of all 24 descriptors that are present within the preceding 30 days. Each descriptor is binary (present or absent). The weights range from 1 to 8: CNS descriptors (seizure, psychosis, organic brain syndrome, visual disturbance, cranial nerve disorder, lupus headache, CVA, vasculitis) = 8 each; renal (casts, hematuria, proteinuria, pyuria) = 4 each; musculoskeletal (arthritis, myositis) = 4 each; mucocutaneous (rash, alopecia, mucosal ulcers) = 2 each; serosal (pleurisy, pericarditis) = 2 each; immunologic (low complement, increased DNA binding) = 2 and 4 respectively; constitutional (fever, thrombocytopenia, leukopenia) = 1 each. The maximum possible score is 105. Scores of 0 indicate no activity, 1-5 mild, 6-10 moderate, 11-19 high, and 20 or greater very high disease activity. The SLEDAI-2K does not include anti-dsDNA in the definition of increased DNA binding — any laboratory elevation is sufficient.

Score Interpretation

The SLEDAI-2K is the most widely validated and utilized disease activity measure in systemic lupus erythematosus. Its clinical significance lies in several key domains. First, it provides a standardized, reproducible assessment of global disease activity that can be reliably tracked longitudinally. A minimum clinically important difference (MCID) of 4 points has been established, allowing clinicians to meaningfully assess treatment response. Second, SLEDAI-2K is the primary endpoint in most SLE clinical trials, including the pivotal BLISS trials (belimumab), the LUNAR trial (rituximab), and the ALMS trial (mycophenolate). Regulatory approvals for belimumab, the first targeted biologic for SLE, were based on SLEDAI-2K response criteria. Third, the weighted scoring system appropriately reflects the clinical significance of different manifestations — CNS involvement carries the highest weight (8 points) consistent with its prognostic importance, while constitutional symptoms carry lower weight (1 point). Fourth, SLEDAI-2K correlates with established damage indices (SLICC/ACR Damage Index), predicts future disease activity and damage accrual, and responds to effective therapy. Fifth, the SLEDAI-2K has been validated against physician global assessment, other disease activity instruments (BILAG, ECLAM, SLAM, RAPID3), and demonstrates excellent psychometric properties across diverse populations. The SLEDAI-2K does not capture all aspects of SLE activity — longer assessment tools like BILAG-2004 provide greater granularity for specific organ systems. However, SLEDAI-2K offers the advantage of simplicity, speed (2-5 minutes to complete), and widespread familiarity. It is recommended by EULAR, ACR, and multiple international lupus organizations for routine clinical assessment. The SLEDAI-2K is also used to define lupus low disease activity state (LLDAS) when combined with physician global assessment and prednisone dose criteria.

Reference Ranges